Vera Therapeutics, Inc. $VERA Shares Sold by Siren L.L.C.

Key Points

• Siren L.L.C. holds a $17.95 million stake in Vera Therapeutics, having reduced its position by 1.5% by selling 11,249 shares in the first quarter.
• Vera Therapeutics recently reported a loss of $1.20 earnings per share for the quarter, missing the consensus estimate of ($0.82), while analysts forecast a future loss of -2.89 EPS for the year.
• Equities analysts have set varied price targets for Vera Therapeutics, with JPMorgan lowering its target from $56 to $53, but overall, the stock maintains an average target price of $63.00 with a "Moderate Buy" rating.

Siren L.L.C. lessened its position in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 1.5% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 747,216 shares of the company's stock after selling 11,249 shares during the quarter. Vera Therapeutics accounts for 1.0% of Siren L.L.C.'s portfolio, making the stock its 25th biggest holding. Siren L.L.C. owned 1.17% of Vera Therapeutics worth $17,948,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in VERA. Vestal Point Capital LP bought a new stake in shares of Vera Therapeutics during the fourth quarter worth $45,462,000. Price T Rowe Associates Inc. MD raised its stake in Vera Therapeutics by 8.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 4,754,832 shares of the company's stock valued at $114,212,000 after buying an additional 377,783 shares during the last quarter. Paradigm Biocapital Advisors LP increased its stake in Vera Therapeutics by 31.0% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 1,437,339 shares of the company's stock valued at $60,785,000 after purchasing an additional 340,488 shares in the last quarter. T. Rowe Price Investment Management Inc. lifted its position in Vera Therapeutics by 18.4% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 1,675,367 shares of the company's stock worth $40,243,000 after acquiring an additional 260,188 shares during the period. Finally, MPM Bioimpact LLC purchased a new stake in Vera Therapeutics in the fourth quarter valued at approximately $10,902,000. Institutional investors own 99.21% of the company's stock.

Vera Therapeutics Stock Down 3.1%

VERA traded down $0.76 on Friday, reaching $23.77. The company's stock had a trading volume of 1,084,138 shares, compared to its average volume of 1,878,065. The company has a debt-to-equity ratio of 0.16, a current ratio of 17.03 and a quick ratio of 17.03. The business's 50 day moving average is $22.28 and its 200 day moving average is $23.26. The stock has a market cap of $1.52 billion, a price-to-earnings ratio of -6.64 and a beta of 1.17. Vera Therapeutics, Inc. has a 1 year low of $18.53 and a 1 year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($1.20) EPS for the quarter, missing analysts' consensus estimates of ($0.82) by ($0.38). During the same quarter in the previous year, the company posted ($0.62) EPS. As a group, research analysts forecast that Vera Therapeutics, Inc. will post -2.89 EPS for the current fiscal year.

Insider Transactions at Vera Therapeutics

In other Vera Therapeutics news, Director Patrick G. Enright acquired 209,393 shares of the firm's stock in a transaction on Monday, June 23rd. The stock was purchased at an average price of $20.87 per share, with a total value of $4,370,031.91. Following the completion of the acquisition, the director directly owned 3,569,522 shares in the company, valued at $74,495,924.14. This trade represents a 6.23% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 16.30% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

VERA has been the subject of a number of recent analyst reports. Scotiabank restated an "outperform" rating on shares of Vera Therapeutics in a research report on Tuesday, June 3rd. Wolfe Research reissued a "peer perform" rating on shares of Vera Therapeutics in a research note on Monday, August 4th. JPMorgan Chase & Co. dropped their price target on shares of Vera Therapeutics from $56.00 to $53.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Guggenheim restated a "buy" rating on shares of Vera Therapeutics in a research note on Tuesday, June 3rd. Finally, HC Wainwright restated a "buy" rating and issued a $85.00 price target (up previously from $75.00) on shares of Vera Therapeutics in a research report on Monday, June 2nd. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $63.00.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.